MedPath

Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.

Not Applicable
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000050723
Lead Sponsor
Kobe University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

(i) Patients who have requested not to participate in this study based on publicly available information. (ii) Other patients deemed ineligible by the principal investigator

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath